A patient is in pulseless arrest and the EKG shows asystole. What is the drug used in ACLS for this rhythm?

Choice A rationale Adenosine is used to treat stable narrow-complex supraventricular tachycardia by slowing conduction through the atrioventricular node. It has a very short half-life and effectively stops the heart for a few seconds to allow the natural pacemaker to take over. It has no therapeutic value in asystole, where there is already a total absence of electrical activity. Administering it in a pulseless arrest with a flat-line rhythm would be clinically inappropriate and ineffective. Choice B rationale Amiodarone is indicated for shockable rhythms such as ventricular fibrillation and pulseless ventricular tachycardia. In these cases, it helps stabilize the cardiac membrane to allow defibrillation to be more successful. Asystole is a non-shockable rhythm characterized by a lack of electrical activity. Since there is no rhythm to convert or stabilize, amiodarone provides no benefit during the management of asystole and is not part of the standard ACLS protocol for this rhythm. Choice C rationale Atropine was previously used in the ACLS asystole algorithm to block vagal tone, but it was removed from the guidelines because clinical evidence showed it did not improve outcomes or survival to discharge for cardiac arrest patients. While it remains the first-line drug for symptomatic bradycardia with a pulse, it is no longer recommended for pulseless arrest rhythms. Current science prioritizes vasopressors like epinephrine to improve perfusion to the heart and the brain. Choice D rationale Epinephrine is the primary medication used in the management of asystole. It is an alpha-adrenergic agonist that causes systemic vasoconstriction, which increases the pressure in the aorta during the relaxation phase of CPR. This increased pressure improves blood flow to the coronary arteries and the brain. By improving myocardial perfusion, epinephrine increases the likelihood that a spontaneous rhythm will return. It is typically administered in 1 mg doses every three to five minutes.